Sweet's syndrome is an autoimmune inflammatory condition, characterized by erythematous plaques infiltrated by neutrophils limited to the dermis. If the infiltrate just present in or extend to the subcutaneous tissue, then it will be labeled as subcutaneous Sweet's syndrome. Due to the rarity of this condition, its association with other medical conditions is inconclusive.
Introduction
Sweet's syndrome (SS), or acute febrile neutrophilic dermatosis, was first described in 1964 by Robert Sweet in a group of 8 female patients 1 . It typically presents with the following clinical triad: erythematous cutaneous plaques infiltrated by mature neutrophils, in association with fever and leukocytosis 1, 2 . Criteria for diagnosing SS are outlined in table 1. Histologically, SS is characterized by diffuse neutrophilic infiltrate in the upper dermis with leukocytoclasia but no true vasculitis 2 . Table 1 . Criteria for diagnosing Sweet's syndrome 4, 8, 10 Major criteria 1. Abrupt onset of painful erythematous plaques or nodules.
2.
Histopathologic evidence of a dense neutrophilic infiltrate without evidence of leukocytoclastic vasculitis.
Minor criteria
1. Pyrexia >38°C 2. Association with an underlying hematologic or visceral malignancy, inflammatory disease, or pregnancy, OR preceded by an upper respiratory or gastrointestinal infection or vaccination 3. Excellent response to treatment with systemic corticosteroids or potassium iodide 4. Abnormal laboratory values at presentation (three of four): erythrocyte sedimentation rate >20 mm/hr; positive C-reactive protein; >8,000 leukocytes; >70% neutrophils
* Two major and two minor criteria are needed for the diagnosis.
The pathogenesis of this condition is still not well known, but an immune etiology has been implicated 3 .SS presents in three clinical settings: classical (or idiopathic), malignancyassociated, and drug-induced 4 .Classical SS is often preceded by an upper respiratory tract infection and may be associated with inflammatory bowel disease and pregnancy 4 .Variants of SS include: plaque, bullous and vesicular, subcutaneous SS, neutrophilic dermatosis of dorsal hands, pustular variant with ulcerative colitis and erythema nodosum-like picture 4 .
Although SS is primarily a dermal process, the neutrophilic infiltrate may spread to the underlying subcutaneous tissue 1, 4, 6, 7 .The term subcutaneous SS is recommended only for cases in which the neutrophilic infiltrate is exclusively or predominantly located in the subcutaneous tissue, regardless of whether the infiltrate predominates in the fat lobules or septae, although lobular predominance is more frequent 1, [7] [8] [9] [10] . The clinical manifestations in most cases of subcutaneous SS are nodules, whereas it is mostly plaques in classic SS 9, 11 .
Till now, there have been four reports of progressive bilateral sensory neural hearing loss (PBSNHL) in association with SS [12] [13] [14] [15] . An autoimmune process targeting the inner ear may be responsible about PBSNHL 16, 17 .We present a 43 year old male patient with PBSNHL who underwent cochlear implantation. Two months later he developed skin lesions consistent with subcutaneous SS, which were well controlled with systemic steroids and cyclosporine.
Case Report:
A 43 year old male patient was followed at the Ear Nose Throat(ENT) clinic as a case of idiopathic progressive bilateral sensory neural hearing loss (PBSNHL) since 3 years, who underwent cochlear implantation. Two years after the onset of PBSNHL, he developed scleritis and followed at the Ophthalmology clinic.
He was given intravenous methylprednisolone 1000mg for 3 days then he was maintained on oral prednisolone 60 mg per day for 1 week which was tapered slowly over 4 months.
He was referred to our clinic, two months after cochlear implant, due to linear (sporotrichoid) tender erythematous elevated painful nodules over both forearms. One week later he presented with painful erythematous plaques over left leg, which ulcerated over the next couple of weeks (figure 1). Skin biopsy was done from the leg nodule; showing spongiosis and mild neutrophilic infiltration of the epidermis with perivascular mixed infiltrate in the dermis ( figure 2A ). The main pathology was located in the subcutaneous tissue; showing dense neutrophilic infiltrate within the fat lobules, ( figure 2B, 2C ). ZiehlNeelsen (ZN) and Periodic-Acid Schiff (PAS) stains were negative. The patient was given oral clarithromycin 500 mg twice daily for two weeks and prednisolone 40 mg per day. The skin ulcer and the indurated erythematous plaques improved after 5 weeks of treatment. The lesions recurred after six months and did not respond to prednisolone (40 mg/day) alone; so cyclosporine 300mg per day was added after 8 weeks of initiating prednisolone. The patient was maintained on this regimen for three months, before tapering was initiated over the following 7 months. The patient is currently off treatment and the lesions completely resolved (figure 3).
Discussion:
Sweet's syndromeis considered a multisystemic inflammatory condition. The diagnostic criteria for classical SS were originally proposed by Su . The lesions may also be distributed in a sporotrichoid pattern 18 , which was seen in our patient.
Since its initial description, SS has been reported to be associated with numerous conditions 4, 9, 10, 12 , as outlined in table 2. The pathogenesis of SS is mostly related to abnormal regulation of the immune system, involving various inflammatory cells 4, 10, 20 .
The rapid response of SS to systemic corticosteroids is in support of its immunological etiology 4, 12, 21 . A classification of neutrophilic dermatoses according to the main location of the neutrophilic infiltrate has been proposed 9 , as summarized in table 3.
Systemic corticosteroids are the first line and best choice treatment for SS. Other firstline oral systemic medications are potassium iodide and colchicine. Second-line oral systemic treatments include cyclosporine, dapsone, indomethacin and clofazimine 4, 10, 12 .
Cyclosporine was used effectively as a steroid-sparing agent in our patient.
Although SS is primarily a dermal process, the neutrophilic infiltrate may spread into the underlying subcutaneous tissue with an associated neutrophilic panniculitis 1, 4, 6, 7 .
The term subcutaneous SS is recommended only for cases in which the neutrophilic infiltrate is exclusively or predominantly located in the subcutaneous tissue 1, 7-10 . In our patient, there was a neutrophilic lobular panniculitis. We performed many tests and imaging studies to look for a possible cause of his neutrophilic lobular panniculitis; these causes are shown in table 4. After exclusion of these causes, we applied the diagnostic criteria for the diagnosis of SS, and he fulfilled them. Therefore, our case fits well the diagnosis of subcutaneous SS.
Up to date only 21well documented cases of subcutaneous SS have been reported in the literature (table 5) 5,22-38 . Most of these cases are associated with myeloid disorders. In general, the associated diseases in patients who have subcutaneous SS are the same as those of classic SS 9 , including both hematologic dyscrasias 39, 40 and solid tumors 42 .
In subcutaneous SS, lesions consist of multipleerythematous tender nodules or plaques 9, 11, 23, 28, 31 . Lower extremities are most commonly involved and rarely the lesions may become ulcerated 23, 28, 31 . Lesions usually appear and resolve in a short period of time 9 . When lesions resolve, they can leave hyper pigmentation and/or atrophicscars 25 . Skin lesions are usually accompanied by systemic symptoms like fever and malaise 24, 26, 31 . Subcutaneous SS in our patient was unusual in having ulceration and absence of constitutional symptoms, but was similar to other reported cases in term of rapid resolution, recurrence and healing with mild atrophic scar and post inflammatory hyper pigmentation. Histopathologic description of subcutaneous SS is not mentioned in most reported cases 9 . Usually biopsies show a dense infiltrate of mature neutrophils in either the adipose tissue alone or it may be seen mainly in the subcutaneous fat with a less impressive infiltrate in the overlying dermis 7, 27 . Within the subcutaneous fat, the neutrophilic infiltrate is most frequently present in the lobules 20, 22, 23, 25, 33, 34, 37, 38 , less commonly in the septae 20, 27, 30, 35 , or both 24, 31, 39, 36, 40, 41 . Vasculitis was absent in all reported cases 9 . Occasionally, some mononuclear epithelioid cells may be found in the subcutaneous tissue 24 , without necrosis of the adipocytes.
Progressive Bilateral Sensory Neural Hearing Loss was first described by McCabe in 1979 16 . The clinical picture is variable with rapidly fluctuating progressive loss of hearing in both ears over a period of weeks to months 16 . Nearly 15% of patients have other systemic "autoimmune" diseases such as multiple sclerosis, inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, and ankylosing spondylitis 12, 43 . The hearing was restored in most patients after the administration of high doses of oral steroids 16 . The observed clinical response to corticosteroid and immunosuppressant therapy supports an immunological etiology targeting the inner ear 43 .Some patients with PBSNHL fail to respond to any medical intervention and the gradual hearing loss progresses to complete deafness, which necessitates cochlear implantation 12, 17 . Ourpatient also failed to respond to systemic treatment, so he underwent cochlear implantation as well.
Till now, there have been four case reports of classical SS following PBSNHL (table 6) 12-15 . Our case is the first, up to our knowledge, of PBSNHL that is followed by subcutaneous SS. The PBSNHL did not improve with conservative measures and the patient underwent cochlear implant as seen in two other patients who had PBSNHL associated with SS 13,14 . Definitive classification of either SS or PBSNHL as an autoimmune disorder cannot be made with any degree of certainty at this time 43 . Whether SS and PBSNHL are related to a single common immunologic defect in our patient is something that we cannot assume. However, the triggering factor for PBSNHL may have resulted in an immunologic cascade that led to the development of subcutaneous SS.
The association of both SS and PBSNHL with more common systemic autoimmune diseases, such as inflammatory bowel disease and rheumatoid arthritis, suggests that the affected patients must be investigated and studied to elucidate a common immunologic role and to rule out other associated autoimmune diseases 12 .
Conclusion:
The precise association between subcutaneous SS and PBSNHL has not been clearly elucidated. However, the association of both with each other supports the immunological etiology of both. The affected patients must be thoroughly investigated and studied to elucidate a common immunologic role and to rule out other associated immune mediated diseases.
